SSAT Research Publications 2008 - 2014

St Stephens AIDS Trust
Clinical Research Publications 2008 2014
ST STEPHENS AIDS TRUST CLINICAL RESEARCH PUBLICATIONS 2008 - 2014
St Stephens Centre, 369 Fulham Road, London SW10 9NH

Tel: 020 3315 6136
www.ssat.org.uk
Registered Charity: 11034163
Registered in England Company Number: 7134218
St Stephens AIDS Trust

Clinical Research Publications 2008 2014
INTRODUCTION
The St Stephens AIDS Trust is a UK clinical research charity
based at the Chelsea and Westminster Hospital in London.
The Charity was founded in 1991 by Professor Brian
Gazzard and a team of colleagues in response to the HIV/
AIDS global pandemic and its impact on people effected
by and living with HIV in the United Kingdom.
St Stephens AIDS Trust mission statement is to:
promote clinical research into the treatment of HIV and

those infections and malignancies associated with the
acquired immunodeficiency syndrome (AIDS), in particular
the research undertaken at the Chelsea and Westminster
Hospital, and to publish such research. It also promotes
education regarding all aspects and matters relating to HIV
by providing information, training and advice throughout
the world.
Over the last 30 years the Charity has been at the
forefront of clinical research studies, from the early
nucleoside reverse transcriptase inhibitor studies in the
1980s, to the current range of successful highly active antiretroviral therapy studies. The Charitys research activities
have produced, in the last 10 years alone, over 500 clinical
research papers. A selection of some 300 of these papers
has been collected together in this publication.
Charity has developed a strong track record in clinical

research through the continued investment in its research
infrastructure and capability, such as its dedicated
Phase IIV PK and Clinical Trials Unit at the Chelsea and
Westminster Hospital. As well as these physical facilities,
the Charity has the capability to sponsor and manage
multi-centred clinical research studies, in the UK and
internationally, through its established service teams in
regulatory, compliance, project management, logistics,
data management and statistics. A range of leading
medical and scientific experts in HIV medicine, immunology
and infectious diseases supports this infrastructure and
capability in clinical research.
As the selection of papers included in this publication
suggest, the Charity has successfully managed a diverse
range of relationships and partnerships. These include
many international pharmaceutical companies; a number
of influential global NGOs (Bill and Melinda Gates
Foundation, International AIDS Vaccine Initiative); key
UK public research bodies (MRC, NHIR, Public Health);
academic institutions from the UK and across the world;
and, as equally important, individual researchers, scientists
and clinicians.
If you are interested in finding out more about the work of the Charity, exploring possible clinical research collaborations and
partnerships or accessing its managed services for conducting clinical research in the UK and internationally, please contact:
General (Charity) enquiries: Linda Connor, Admin Manager: 020 3315 6136
PK and Clinical Trials Unit: Carl Fletcher, Associate Director: 020 3325 6325
Clinical Research Organisation Services: Ruth Bateson, Associate Director: 020 3315 6563
CLINICAL RESEARCH PUBLICATIONS 2008-2014
2014
Writing group. Williams I, Churchill D, Anderson J, Boffito M,
Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher
M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson
M, Khoo S, Leen C, Marshal N, Nelson M, Orkin C, Paton N,
Philips, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski
A, Waalsh J, Waters L, Wilkins E, Winston A, Youle M
British HIV Association Guidelines for the treatment of
HIV 1 positive adults with Antiretroviral therapy 2012
(updated 2013)
HIV Med 2014 Mar; 15 supp 2. 1-9
Parikh ND, Martel-Laferriere V, Kushner T, Childs K, Vachon

ML, Dronamraj D, Taylor C, Fiel MI, Schaino T, Nelson M,
Agarwal K, Dieterich DT
Clinical factors that predict noncirrhotic portal
hypertension in HIV infected patients: Proposed
diagnostic algorithm
J Infect Dis 2014 Mar; 209 (5): 734-8
Chacko L, Chamberlain F, Mandalia S, Nelson M
Do resistance patterns vary between different FTC

contain drug regimens?
J Infect 2014 Feb 8 2014
McFaul K, Liptrott N, Cox A, Martin P, Egan D, Owen A, Kelly

S, Karolia Z, Shaw K, Bower M & Boffito M.
Evolution of cellular and viral resistance in HIV patients

diagnosed with lymphoma receiving chemotherapy and
combination antiretroviral therapy.
HIV Medicine 2014, 15 (suppl 3) 53
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S,

Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post Fisher M, Ainsworth J, Jose S, Leen
C, Nelson M, Anderson J, Sabin C: for the UK Collaborative
HIV cohort (UK CHIC) study
Impact on life expectancy of HIV 1 positive individuals
of CD4+ cell count and Viral load response to
antiretroviral therapy: UK cohort study
AIDS 2014 Feb 19
Longley J, Redlin S, Balachandran K, Holmes P, Nelson M &

Bower M.
Non-Hodgkins lymphoma (NHL): Does being on cART
before diagnosis make a difference?
Tull T, Papineni P, Cook C, Mee J, Bower M, Morar N,

Nelson M
Paraneoplastic pemphigus in patient infected with HIV

Clin Exp Dermatol. 2014 Jan ; 39 (1): 83-5
Raman L, Nelson M
Prospective stage stratified approach to AIDS related

Kaposis Sarcoma
J Clin Virol 2014 Feb 2
Smith M, Pealing J, McCann S, Balachandran K, Nelson M &

Bower M
Second malignancies in patients with Kaposis sarcoma
(KS): Does systemic chemotherapy contribute to risk?
HIV Medicine 2014, 15 (suppl 3) 8.
Keay R, Singh G, Abdul-Latif M, Rayment M, Nelson M
Shigella flexneri enteritis in risk- taking HIV infected

MSM
Chacko L, Chamberlain F, Mandalia S, Nelson M
J Infect 2014 Jan; 68 (1); 103-4
J Acqui Immune Defic Syndr 2014 Jan 1; 65 (1): 78-81
Ferras Alwan, Annie He, Silvia Montoto, Shireen Kassam,

Matthew Mee, Fiona Burns, Simon Edwards, Andy Wilson,
Melinda Tenant-Flowers, Robert Marcus, Kirit M. Ardeshna,
Mark Bower, Kate Cwynarski.
Five-year safety evaluation of Maraviroc in HIV 1

infected treatment experienced patients
Nightingale A, Ratcliffe D, Leonidou L, Margetts A, Asboe D,

Gazzard B, Catalan J, Barber TJ.
HIV-related neurocognitive impairment screening: the
patients perspective on its utility and psychological
impact.
AIDS Care. 2014 Mar 13
Dhoot S, Balachandran K, Tittle V, Bunker C, Nelson M,

Kelleher P & Bower M
Immunological function in HIV-seronegative men

who have sex with men (MSM) and Kaposis sarcoma
(KS)
The addition of Rituximab to CODOX-M/IVAC

chemotherapy in the treatment of Burkitt lymphoma is
safe and associated with increased efficacy in the HIV
positive population.
EHA 2014.
Bulteel N, Banso-Matharu L, Churchill D, Dunn D, Bibby D,

Hill T, Nelson M, CHIC study group; UK Drug resistant Database (UK HDRD) Study Group
The emergence of drug resistant HIV variants at
virological failure of HAART combination containing
efavirenz, Tenofovir and lamivudine or emtricitabine
within the UK collaborative HIV cohort
J Infect 2014 Jan; 68 (1): 77-84
Rayment M, Doku E, Thornton A, Pearn M, Sudhanva M,

Jones R, Nardone A, Roberts P, Tenant-Flowers M, Anderson
J, Sullivan AK and Mark Atkins
2013
Jackson A, Klverpris HN, Boffito M, Handley A, Atkins M,
Hayes P, Gilmour J, Riddel L, Chen F, Bailey-Tippets M, Walker B, Ackland J, Sullivan M, Goulder P
A Randomised, Placebo-Controlled, First-In-Human
Study of a Novel Clade C Therapeutic Peptide Vaccine
Administered Ex Vivo to Autologous White Blood Cells
in HIV Infected Individuals.
PLoS One. 2013;17.
Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR,

Domingo P, Granier C, Pearce H, Sedani S, Gartland M,
Team A.
96-Week results of abacavir/lamivudine versus

tenofovir/emtricitabine, plus efavirenz, in antiretroviralnaive, HIV-1-infected adults: ASSERT study.
Antivir Ther. 2013 Jul 31
Pozniak AL, Arribas JR.
A benchmark for management of drug resistant HIV.

Lancet Infect Dis. 2013 Jul;13(7):561-2
Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S,
Nelson M, Montoto S; Tennant-Flowers M, Burns F, Marcus
R, Edwards SG, Cwynarski K
A retrospective multi-centre analysis of treatment
intensification for HIV positive patients with high risk
diffuse large B cell lymphoma
Leuk Lymphoma 2013 Sep; 54 (9): 1921-7
Martin TC, Martin NK, Naresh KN, Nelson M
A traumatic splenic rupture secondary to chronic HIV

infection
Int J STD AIDS 2013 Dec; 24 (12) 989-91
Revell AD, Wang D, Wood R, Morrow C, Templeman H,

Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ebe L, Wensing
A Reiss P, van Sigham AI, Nelson M, Emery S, Montanr JSm,
Lane HC, Larder BA;on behalf of RDI group
An update to the HIV TrePS system: the development
of new computational models that do not require a
genotype to predict HIV treatment outcomes
J Antimicrob Chemother 2013 Nov 24
Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D,

Kingston MA, Thng C, McCormack S, Gill ON, Nardone A;
Audit of HIV testing frequency and behavioural
interventions for men who have sex with men: policy
and practice in sexual health clinics in England
Sex Transm Infect 2013; 89:404-8
Automatic Oral Fluid-Based HIV Testing in HIV Screening

Programmes
HIV Med 2013; 14 Suppl 3:49-52
Abdel Malek R, Cox S, Bower M, Farag D & Alsirafy S.
Availability of informal caregivers for palliative care

patients with cancer: Is there a difference between
higher and lower income settings?
Eur J Cancer, 2013: 49/S2, S291.
Mehta P, Nelson M, Brand A, Boag F

Avascular necrosis in HV
Hematol Int. 2013 Jan; 33 (1): 235-8

Girad PM, Nelson M, Mohammed P, Hill A, van Delft Y,
Moecklinghoff C
Can we stop CD4+ testing in patients with HIV 1 RNA

suppression on antiretroviral treatment?
AIDS 2013 Nov 13; 27 (17): 2759-63
Jagit Singh GK, Ijaz S, Rockwood N, Farnworth SP, Devitt

E, Atkins M, TedderR, Nelson M.

Chronic Hepatitis E as a cause for cryptogenic cirrhosis

in HIV
J. Infect 2013 Jan; 66 (1): 103-6
Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N,

Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M
Coadministration of atazanavir-ritonavir and
zinc sulfate: impact on hyperbilirubinemia and
pharmacokinetics
Antimicrob Agents Chemother. 2013;57:3640-4.
Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd

P, Dejesus E, Antunes F, Arasth K, Moyle G, Rizzardini G,
Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS,
Cheng AK
Cobicistat Versus Ritonavir as a Pharmacoenhancer
of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil
Fumarate in Treatment-Naive HIV Type 1-Infected
Patients: Week 48 Results.
J Infect Dis. 2013;208:32-9
Bower M, Della Pria A, Flook M, Hayward K, Januszewski A,

Williams J & Nelson M
Comparison of two diagnostic criteria schemes for
multicentric Castlemans disease in 72 cases.
2013 continued
Revell AD, Wang D, Wood R, Morrow C, Templeman H,
Hamers RL, Alvarez-Uria G, Steinu-Cercel A, Ene L. Wensing
AM, DeWolf F, Nelson M, Montaner JS, Lane HC, Larder BA,
RDI study group
Computation models can predict response to HIV
therapy without a genotype and may reduce treatment
failure in different resource limited settings
J Antimicrob Chemother 2013 June; 68 (6); 1406-14
Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA,

Kaplan R, Lazzarin A, Valdez H, Goodrich J, Mori J, Craig C,
Tawadrous M
Efficacy and safety of lersivirine (UK-453,061) versus

efavirenz in antiretroviral treatment-naive HIV-1infected patients: week 48 primary analysis results from
an ongoing, multicenter, randomized, double-blind,
phase IIb trial
J Acquir Immune Defic Syndr. 2013 Feb
1;62(2):171-9
Nithianathan V, Singh GKJ, Bower M & Nelson M
Raben D, Delpech V, de Wit J, Sullivan A, Lazarus J, Dedes

N, Coenen T, Lundgren J;
Emerging patterns of integrase inhibitor

resistance
HIV Med 2013; 14 Suppl 3:1-5
OConnor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay

P, Chadwick D,, Fisher M, Ainsworth J, Gilson R, Mackie N,
Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman
A, Post F, Johnson M, Sabin CA, Phillips AN
Conclusions from the HIV in Europe Copenhagen 2012

Conference and ways forward: working together for
optimal HIV testing and earlier care
Rice B, Elford J, Yin Z, Kruijshaar M, Abubakar I, Lipman M,

Pozniak A, Kall M, Delpech V.
Decreasing incidence of tuberculosis among

heterosexuals living with diagnosed HIV in England and
Wales.
AIDS. 2013 Apr 24;27(7):1151-7.
Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C,

Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie
J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T,
Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D,
Underwood M, Griffith S, Min S; extended SAILING Study
Team.
Dolutegravir versus raltegravir in antiretroviralexperienced, integrase-inhibitor-naive adults with HIV:

week 48 results from the randomised, double-blind,
non-inferiority SAILING study
Lancet. 2013 Aug 24;382(9893):700-8.
Beckett H, Abdul-Latif M, Mandalia S, Singh GKJ, Bower M &

Nelson M.
Failure to achieve a CD4+ cell count response in

combination antiretroviral therapy despite consistent
viral load suppression
AIDS 2013 Dec 11
Rayment M, Sullivan AK
Failure to test for HIV infection; A medicolegal

question?
Casebook 2013 21; 1: 7
Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser

S, Leon A, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A,
Vassilenko A, Hadziosmanovic V, Krasnov M, Snnerborg A,
Clumeck N, Gatell J, Gazzard B, Monforte Ad, Rockstroh J,
Lundgren JD
Feasibility and Effectiveness of Indicator ConditionGuided Testing for HIV: Results from HIDES I (HIV
Indicator Diseases across Europe Study
PLoS One 2013; 8(1):e52845. Epub 2013 Jan 15
Effect of bisphosphonates on the treatment of BMD

abnormalities in an HIV-1 minfected cohort
Lewitsching S, Gedela K, Toby M, Kulasegaram R, Nelson M,

ODoherty M, Cook GJ
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B; Gilson R, Orkin C, Johnson M, Palfreeman
A, Chadwick D, Leen C; Schwenk A, Anderson J, Gompels
M, Dunn D, Khoo S, Sabin C
Eur J Nucl Med MoL Imaging 2013 Sept; 40 (9); 1420 -7
Effects of age on antiretroviral plasma drug

concentration in HIV infected subjects undergoing
routine therapeutic drug monitoring
J Antimicrob Chemother 2013 June 68 (6) 1354-9
F-FDG PET/CT in HIV related central nervous system

pathology
Vispo E, Cevik M, Rockstroph JK, Barreiro P, Nelson M,

Scourfirled A, Wasmuth JC, Boesecke C, Soriano V,
European Network of Clinic Trials (NEAT)
Genetic determinants of idiopathic noncirrhotic ports

hypertension in HIV infected patients
Clin Infect Dis 2013 April; 56 (8): 1117 - 22
Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D,

Kingston MA, Thng C, McCormack S, Gill ON, Nardone A;
GUMNet.
Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D,

Cummins N, Dalmau D, Dehovitz J, Lehmann C, Sullivan A,
Woolley I, Kuller L, Neaton JD, Tracy RP
Sex Transm Infect 2013; 89:404-8
J Am Heart Assoc 2013; 2(4):e000264
Audit of HIV testing frequency and behavioural

interventions for men who have sex with men: policy
and practice in sexual health clinics in England
C. Cevik M, Oh K, Scott S, Tan J, Bower M & Nelson M
Hepatic safety profile of antiretrovirals in individuals

infected with HIV and chronic hepatitis
INSIGHT SMART Study Team. HIV Replication Alters the

Composition of Extrinsic Pathway Coagulation Factors
and Increases Thrombin Generation.
Bashford J, Nelson M, Bower M, Atkins M
JC a forgotten foe or a foe to be forgotten

IV Med 2013 May; 14 (5): 326
Martin TC, Martin NK, Hickman M, Vickerman P, Page EE,

Everett R; Gazzard BG, Nelson M
Gathogo EN, Hamzah L, Hilton R, Marshall N, Ashley C,

Harber M, Levy JB, Jones R, Boffito M, Khoo SH, Drage M,
Bhagani S, Post FA
AIDS 2013 Oct 23; 27 (16): 2551-7
Int J STD AIDS.
Hepatitis C Virus reinfection incidence and treatment

outcomes among HIV positive MSM
Coutinho R, Flook M, Dalla Pria A, Gandhi S, Bailey K, Fields

P, Cwynarski K, Wilson A, Tenant-Flowers M, Marcus R,
Orkin C, Gribben JG, Montoto S, Bower M
HIV status does not influence the outcome of patients
diagnosed with DLBCL treated with R-CHOP in the
HAART era
Haematologica, 2013; 98 (s1) 129.
Pozniak A, Rackstraw S, Deayton J, Barber T, Taylor S, Manji

H, Melvin D, Croston M, Nightingale S, Kulasegaram R,
Pitkanen M, Winston A.
HIV-associated neurocognitive disease: case studies and

suggestions for diagnosis and management in different
patient sub-groups.
Antivir Ther. 2013 Mar 21
Lawton MD, Nathan M, Asboe D.
HPV vaccination to prevent anal cancer in men who

have sex with men
Sex Transm Infect. 2013 Aug;89(5):342-3.
Barton SE and OMahoney C
HPV vaccination; reaping the rewards of the appliance

of science.
BMJ 2013;346:f2184
Van de Velde V, Nelson M, Bower M & Sonecha S.
Indications for changing to raltegravir therapy in patient

sixth pre-existing undetectable viral load
Kidney transplantation in HIV-positive adults: The UK

experience.
Bull L, Bower M & Nelson M.
Long-term therapeutic success of etravirine in switch

and naive patients.
Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ,

Andersen O, Imami N
Low-dose growth hormone for 40 weeks induces

HIV-1-specific T cell responses in patients on effective
combination anti-retroviral therapy.
Clin Exp Immunol. 2013;173:444-53
Hughes G, Alexander S, Simms I, Conti S, Ward H, Powers C,

Ison C; on behalf of the LGV Incident Group.
Lymphogranuloma venereum diagnoses among men
who have sex with men in the UK: interpreting a
cross-sectional study using an epidemic phase-specific
framework.
Sex Transm Infect 2013 Jul 12
Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G,

Carne S, Back DJ, Gill ON
Non-disclosure of HIV status in UK sexual health clinics

a pilot study to identify non-disclosure within a national
unlinked anonymous seroprevalence survey
Sex Transm Infect 2013; 89:120-1. Epub 2013 Feb 13
Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N,

Nelson M; Gazzard BG
Pancreatic insufficiency in patients with HIV
infection:role of didanosine questioned
HIV Med 2013 March; 14 (3): 161-6
2013 continued
Della Pria A, Holmes P, Alfa-Wali M, Fox P, McKenna H,
Nelson M & Bower M
Persistence of anal dysplasia following
chemoradiotherapy for anal cancer
Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski

J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D,
Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M,
Gazzard B, Fast PE, Cox JH, Laufer D
Safety and immunogenicity of DNA prime and modified

vaccinia ankara virus-HIV subtype C vaccine boost in
healthy adults
Clin Vaccine Immunol. 2013 ;20:397-408.
Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips

A, Dunn DT; for the UK Collaborative Group on HIV Drug
Resistance.
Alfa-Wali M, Safarfashandi L, Ion L, Nelson M, Allen-Mersh T

& Bower M.
J Infect Dis. 2013 ;208(9):1459-63.
Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JS,

Lane HC, Larder BA
Bull L, Bower M & Nelson M.
Persistence of HIV-1 Transmitted Drug Resistance

Mutations
Potential Impact of a Free Online HIV Treatment

Response Prediction System for Reducing Virological
Failures and Drug Costs after Antiretroviral Therapy
Failure in a Resource-Limited Setting.
Biomed Res Int. 2013;2013:579741.
Cevik M, Dickinson L, Singh GS, Bower M & Nelson M
Raltegravir (RAL) switch improves hepatitis C

transaminitis in HIV-1 and hepatitis C (HCV) co-infected
individuals.
Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, SegalMaurer S, Bloch M, Garner W, Guy B, Williams S, Chuck S,
Vanveggel S, Deck H, Stevens M
Rilpivirine versus efavirenz in HIV1 infected subjects
receiving emtricitabine/Tenofovir DF: pooled 96 week
data from ECHO and THRIVE studies
HIV Clin Trials 2013 May-June; 14 (3): 81-91
Rayment M, Rae C, Ghooloo F, Doku E, Hardie J, Finlay S,

Gidwani S, Atkins M, Roberts P, Sullivan AK.
Routine HIV Testing in the Emergency Department:
Tough Lessons in Sustainability
HIV Med 2013; 14 Suppl 3:6-9
The HSV 040 Vaccine Study Group
Safety and Immunogenicity of a glycoprotein D genital

Herpes subunit vaccine in healthy 10-17 years of age.
Results from a randomised controlled double blind
trial.
Vaccine 2013 July 9. S0264-410X(13. 891-8
10
Salvage surgery for residual primary anal squamous

cell carcinoma after chemoradiotherapy in HIV-positive
individuals.
Salvage therapy with protease inhibitor sparing

regimens containing etravirine
Barber TJ, Bradshaw D, Hughes D, Leonidou L, Margetts

A, Ratcliffe D, Thornton S, Pozniak A, Asboe D, Mandalia S,
Boffito M, Davies N, Gazzard B, Catalan J.
Screening for HIV-related neurocognitive impairment in

clinical practice: Challenges and opportunities.
AIDS Care. 2013 Jul 22
Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C,

Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug
Resustance Database.
Second-line protease inhibitor-based antiretroviral
therapy after non-nucleoside reverse transcriptase
inhibitor failure: the effect of a nucleoside backbone.
Antivir Ther. 2013;18(2):213-9
Abdul-Latif M, Beckett H, Rayment M, Singh GKJ, Bower M

& Nelson M.
Shigella Flexneri enteritis in risk-taking HIV-infected
MSM a single institution experience
Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D,

Mohabeer M, Gazzard B, Boffito M
Tenofovir, emtricitabine intracellular and plasma, and

efavirenz plasma concentration decay following drug
intake cessation: implications for HIV treatment and
prevention.
J Acquir Immune Defic Syndr. 2013;62:275-81
Samuel M, Jose S, Winston Am Nelson m, Johnson M,

Chadwick D, Fisher M, Leen C, Gomples M, Gilson R, Post F,
Hay P, Sabin C (UK CHIC)
The effects of age on associations between markers
of HIV progression and markers of metabolic
function including albumin, haemoglobulin and lipid
concentrations
HIV Med 2013 Nov 19 doi: 10.1111
Mletzko S, Rai A, Westrop S, Imami N, Shahrabi Y, Della Pria

A, Howell S, Jones M, Gotch F & Bower M
The role of interleukin-6 and Interleukin-6 receptor
in multicentric Castlemans disease: Frequency of
polymorphism
Della Pria A, Flook M, Williams J, Goode E, Berg L, NewsomDavis T, Nelson M & Bower M
The spectrum of non-AIDS defining malignancy: 431
cases
Chamberlain FE, Chacko L, Singh GKJ, Bower M

& Nelson M
The use of azathioprine in HIV-infected individuals

Vishwanath V, Singh GKJ, Dub S, Bower M & Nelson M
The use of dual maraviroc/ritonavir boosted daraunavir

combination in clinical practice
Constandinou T, Vekeria S, Singh GKJ, Bower M & Nelson M

Use of antacid preparations with HAART
Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D,

Cummins N, Dalmau D, Dehovitz J, Lehmann C, Sullivan A,
Woolley I, Kuller L, Neaton JD, Tracy RP; INSIGHT SMART
Study Team.
HIV Replication Alters the Composition of Extrinsic
Pathway Coagulation Factors and Increases Thrombin
Generation
J Am Heart Assoc 2013; 2(4):e000264
Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A,

Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M,
Balogh A, Biguenet S; the ReAL Study Team.
A randomized comparative 96-week trial of boosted

atazanavir versus continued boosted protease inhibitor
in HIV-1 patients with abdominal adiposity.
Antivir Ther. 2012. [Epub ahead of print]
Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ,

Conway B, Tobias JK, Vanhove GF; For the NGX-4010 C119
Study Group
A Randomized, Double-Blind, Controlled Study of
NGX-4010, a Capsaicin 8% Dermal Patch, for the
Treatment of Painful HIV-Associated Distal Sensory
Polyneuropathy.
Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG,

Imani
Are long-term non-progressors very slow progressors?

Insights form the Chelsea & Westminster HIV cohort
1988-2010
PLoS One 2012; 7 (2): e29844
Barber T, Bansi L, Leonidou L, Pozniak A, Asboe D, Nelson

M, Moyle G, Boffito M, Davies N, Thornton S, Catalan J,
Gazzard B
Baseline data from the MSM Neurocog study
J Int AIDS Soc. 2012 ;15:18176.
Ahmed A, Page E, Bower M & Nelson M.
Bocepravir for the treatment of chronic hepatitis C in

HIV co-infected.
Scourfield A, Waters L, Martin T, Mandalia S, Bower M,

Gazzard B & Nelson M.
Can antiretrovirals increase the risk of venous
thromboembolism in HIV infection?
Awoyemi D, Mandalia S, Bower M, Anderson M & Nelson M

Can haemoglobin drop replace rapid virological
response in predicting a sustained virological
response?
2012
Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S,

Imami N.
Waters L, Patterson B, Scourfield A, Hughes A, de Silva S,

Gazzard B, Barton S, Asboe D, Pozniak A, Boffito M
A dedicated clinic for HIV-positive individuals over 50

years of age: a multidisciplinary experience
CCR5 antagonism impacts vaccination response and

immune profile in HIV-1 infection.
Mol Med. 2012;18:1240-8
Int J STD AIDS. 2012;23:546-52
11
2012 continued
Clutterbuck DJ, Flowers P, Barber T, Wilson H, Nelson M,
Hedge B, Kapp S, Fakoya A, Sullivan AK
Clinical Effectiveness Group of British Association
fro Sexual Health and HIV (BASHH) and British HIV
Association (BHIVA)
Int J STD AIDS. 20012 June; 23 (6): 38108
McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D,

McGrath D, Farajallah A, Moyle G.
Scourfield A, Zheng J, Chinthapall S, Waters L, Martin T,

Mandalia S, Nelson M
Discontinuation of Atripla as first-line therapy in HIV-1

infected individuals
AIDS: 2012 Jul 17; 26 (22): 1399-401
Lamorde M, Byakika-Kibwika P, Tamale WS, Kiweewa F, Ryan

M, Amara A, Tjia J, Back D, Khoo S, Boffito M, Kityo C,
Merry C.
Effect of Food on the Steady-State Pharmacokinetics of
Tenofovir and Emtricitabine plus Efavirenz in Ugandan
Adults
Clinical Significance of Hyperbilirubinemia Among HIV1-Infected Patients Treated with Atazanavir/Ritonavir

Through 96 Weeks in the CASTLE Study.
AIDS Res Treat. 2012;105980.
Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM,

Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD,
Winston A
Efficacy and safety of rilpivirine in treatment nave.

HIV-1 infected patients with hepatitis B virus/hepatitis C
virus coinfections enrolled in the Phase III randomised,
double blind ECHO and THRIVE trials
AIDS Patient Care STDS. 2012;26:259-64
CNS effects of CCR% inhibitor in HIV infected subjects:

a pharmacokinetic and cerebral metabolite study
J Antimicrob Chemother. 2012 Jan; 67 (1); 206-12
Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabvin C, Post FA;

UK CHIC/CKD* Study Group
Comparison of CKD-EPI and MDRD to estimate baseline

renal function in HIV positive patients
Nephrol Dial Transplant. 2012 June; 27 (6): 2291-7
Westrop S, Mandalia S, Moyle G, Bower M, Nelson M

& Imami
Compounded Influence of Patient Age, ART Duration

and Time since HIV-1+ Diagnosis Delineates the
Immune Profile of the Ageing Cohort
N. CROI 2012
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I,

Kaiser R, Snnerborg A, Codoer FM, Van Laethem K,
Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe
D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration
in Chain
Declining prevalence of HIV-1 drug resistance in
antiretroviral treatment-exposed individuals in Western
Europe.
Int J STD AIDS. 2012 Aug;23(8):546-52.
Chinthapalli S, Mandalia S, Jones R, Bower M & Nelson M.

Descriptive case series of eight HIV positive patients
with foot stress fractures.
Nelson M, Amaya G, Clumeck N, Arns da Cunha C,

Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A,
Vanveggel S, Boven K; ECHO and THRIVE Study Groups.
J Antomicrob Chemother. 2012 Aug; 67 (*): 2020-8
Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle

M, Khoo SH, Back DJ, Owen A.
Estimation of the effect of SLCO1B1 polymorphisms
on lopinavir plasma concentration in HIV-infected
adults
Antivir Ther. 2012;17:861-8
Thornton A, Rayment M, Mandalia S, Elam G, Atkins M,

Jones R, Nardone A, Roberts P, Tenant-Flowers M, Anderson
J, Sullivan A.
Exploring staff attitudes to routine HIV testing in
non-traditional settings: a qualitative study in four
healthcare facilities.
Sex Transm Infect 2012 ;88:601-6
Mletzko S, Shahrabi Y, Hislop A, Harding V, Nelson M, Gotch

F & Bower M.
Ex-vivo recognition of immediate-early T cell epitopes
within open reading frame ORF50 and K8 of Kaposis
sarcoma-associated herpesvirus (KSHV) by HIV/KSHVcoinfected individuals
Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson

R, Bansi L, Pillay D, Dunn D; on behalf of the UK HIV Drug
Resistance Database and the UK Collaborative HIV Cohort
(UK CHIC) Study Steering Committees.
Frequency and patterns of protease gene resistance
mutations in HIV-infected patients treated with
lopinavir/ritonavir as their first protease inhibitor.
J Antimicrob Chemother. 2012 Apr;67(4):995-1000
12
Manley J, Dunning J, Nelson M, Bower M
HIV associated gastric natural killer? T-cell lymphoma

Int J STD AIDS 2012. Jan; 23 (1): 66-7
Rayment M, Thornton A, Mandalia S, Elam G, Atkins M, Jone

R, Nardone A, Roberts P, Tenant-Flowers M, Anderson J,
Sullivan A.
HIV Testing in Non-Traditional Settings - The HINTS
Study: A Multi-Centre Observational Study of Feasibility
and Acceptability
PLoS One 2012; 7(6):e39530. Epub 2012 Jun 22
Bashford J, Atkins M, Bower M & Nelson M.
How commonly is JC virus detected in the cerebrospinal

fluid of patients with HIV?
Vogel M, Page E, Boesecke C, Reiberger T, SchwarzeZander C, Mauss S, Baumgarten A, Wasmuth JC, Nelson M,
Rockstroph JK, European AIDS Treatment Network (NEAT)
Study Group
Liver fibrosis progression after acute hepatitis C virus
infection in HIV-positive individuals
Clin Infect Dis,. 2012 Feb 12; 54 (4): 556-9
Vrouenraets SM, Wit FW, Garcia EF, Huber M, Brinkman

K, Moyle G, Domingo P, Tarr PE, Podzamczer D, Ristola M,
Gatell JM, Livrozet JM, Furrer H, Reiss P; PREPARE Study
Group.
Longer prior exposure to zidovudine/lamivudinecontaining combination antiretroviral therapy, age,
and male gender are each associated with reduced
subcutaneous adipose tissue.
HIV Clin Trials. 2012;13:103-10.
Beck EJ, Mandalia S, Sangha R, Youle M, Brettle R, Gompels

M, Johnson M, Pozniak A, Schwenk A, Taylor S, Walsh
J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering
Group
SW Worm, M Bower, P Reiss, A Grulich,, E Fontas, F Bonnet,

G Faetkenheuer, M Law, A Phillips, HJ Furrer, W El-Sadr,
O Kirk, L Ryom, D Abrams, A DArminio Monforte, S De
Wit, C Sabin, JD Lundgren on behalf of the D:A:D study
group
Non-AIDS defining malignancies (NADM) and
immunosuppression: The D:A:D study
CROI 2012
Garlassi E, Harding V, Allen H, Allin B, Lee N, Nelson M &

Bower M.
Non-melanoma skin cancers among HIV-infected
persons in the HAART-era
Kober C, Johnson M, Fisher M, Hill, T Anderson J, Bansi L,

Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R,
Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth
J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC)
study
Non-uptake of highly active antiretroviral therapy
among patients with a CD4 count <350 cells ul in the
UK
HIV Med 2012 Jan; 13 (1); 73-8
Bradshaw D, Pallawela S, Nelson M, Scott C, Day C

Otosyphilis: missed opportunities for early
treatment
Sex Transm Infect. 2012 Sept 21
Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M,

Goodier MR
PD-1 Expression on Natural Killers Cells and CD8 (+) T
Cells During Chronic HIV-1 Infection
Viral Immunol. 2012 Aug; 25 (4): 329-32
Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C,

Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D
Lower healthcare costs associated with the use of a

single-pill ARV regimen in the UK, 2004-2008.
Pharmacokinetic and pharmacodynamic analysis of

efavirenz dose reduction using an in vitro-in vivo
extrapolation model
Salvinia Mletzko, Y Shahrabi, M Bower, K Hayward, V Harding, C Boshoff, A Benlahrech, and F Gotch.
Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J,

Gedela K, Abongomera G, Gazzard B, Boffito M.
CROI 2012
Antivir Ther. 2012;17:19-24.
PLoS One. 2012;7(10):e47376
Modification of Dendritic Cell Function by Kaposis

Sarcoma-associated Herpesvirus Suggests a Novel
Immune Evasion Strategy
Clin Pharmacol Ther. 2012;92:494-502.
Pharmacokinetics of abacavir and its anabolite carbovir

triphosphate without and with darunavir/ritonavir or
raltegravir in HIV-infected subjects.
13
2012 continued
Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely
M, di Iulio J, Owen A, Boffito M, Cavassini M, Gnthard HF,
Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger
M, Csajka C; Swiss HIV Cohort Study Group
Population pharmacokinetic analysis and
pharmacogenetics of raltegravir in HIV-positive and
healthy individuals.
Antimicrob Agents Chemother. 2012;56:2959-66.
Tan J, Sonali S, Bower M, Smith B & Nelson M
Reasons for non-utilisation of a home delivery service

among patients stabilised on antiretroviral therapy at 3
outpatient clinic sites
Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N.
The Effect of a 12-Week Course of Omega-3

Polyunsaturated Fatty Acids on Lipid Parameters in
Hypertriglyceridemic Adult HIV-infected Patients
Undergoing HAART: A Randomized, Placebo-Controlled
Pilot Trial.
Clin Ther. 2012;34:67-76
Carr A, Hoy J, Pozniak A.
The ethics of switch/simplify in antiretroviral trials: noninferior or just inferior?

PLoS Med. 2012;9(7):e1001240.
Thomas Newsom-Davis, Paul Fox, Victoria Bradley, Alessia

Dalla Pria, Mark Nelson, Mark Bower
The features and outcome of HIV-associated anal cancer

in screened and unscreened populations
Fakoya I, Johnson AM, Fenton K, Anderson J, Nwokolo N,

Sullivan AK, Munday P, Burns FM
Shavadia J, Shah R, Yonga G, Patel R, Stebbing J, Nelson M
Religion and HIV diagnosis among Africans living in

London
HIV Med 2012; 13:617-22
Myers J, Rayment M, Sonecha S, Moyle G, Boffito M.
Room for manoeuvre when prescribing statins to

dyslipidaemic patients on antiretroviral therapy.
HIV Med. 2012;13(3):190-2.
Kumar N, Bower M, Nelson M
Severe vitamin D deficiency in a patient treated for

hepatitis B with tenofovir
Int J STD AIDS 2012. Jan; 23 (1): 59-60
Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back

D, Khoo S, Davies G
Simultaneous population pharmacokinetic modelling
of atazanavir and ritonavir in HIV-infected adults and
assessment of different dose reduction strategies
Lamorde M, Byakika-Kibwika P, Boffito M, Nabukeera L,

Mayito J, Ogwal-Okeng J, Tjia J, Back D, Khoo S, Ryan M,
Merry C
Steady-state pharmacokinetics of lopinavir plus
ritonavir when administered under different meal
conditions in HIV-infected Ugandan adults
J Clin Oncol 30, 2012 (suppl; abstr e14574
The influence of antiretroviral therapy on QTc interval in

an African cohort
Clin Infect Dis. 2012 Feb 1; 54 (3): 448-9
Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y,

Moecklinghoff
The MONET trial: week 144 analysis of the efficacy of

darunavir/ritonavir DRV/r) monotherapy versus DRV/r
plus two nucleoside reverse transcriptase inhibitors
for patients with viral load <50 HIV-1 RNA copies/Ml at
baseline.
HIV Med. 2012 Aug; 13 (7): 398-405
UK Collaborative Group on HIV Drug Resistance, Dolling

D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown
AL, Churchill D, Williams I, Geretti AM, Phillips A, Mackie N,
Murphy G, Castro H, Pillay D, Cane P, Dunn D, Dolling D.
Time trends in drug resistant HIV-1 infections in the

United Kingdom up to 2009: multicentre observational
study
BMJ. 2012 Aug 21;345:e5253
S. Kassam, M. Bower, S.M. Lee, J. De Vos, P. Fields, S.

Gandhi, M. Nelson, S. Montoto, M. Tenant-Flowers, F. Burns,
R. Marcus, S.G. Edwards, K. Cwynarski,
Treatment intensification for HIV-positive patients
with high-risk diffuse large B-cell lymphoma does not
improve outcome: a retrospective, multi-centre study
EHA 2012
Clutterbuck D, Flowers P, Barber T, Wilson H, Nelson M,

Hedge B, Kapp S, Fakoya A, Sullivan AK
UK national guideline on safer sex advice
International Journal of STD & AIDS 2012; 23
14
Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto

JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W,
Dunkle LM, Vichez RA, Zeinecker J
Vicriviroc plus optimised background therapy for

treatment experienced subjects with CCR5 HIV-1
infection: Final results of two randomised phase III trials
J Infect. 2012 OCT; 65 (4): 326-35 2012
Chemoradiotherapy of anal cancer in HIV patients

causes prolonged CD4 cell count suppression.
HIV Medicine 2011, 12 (Suppl 1), 7. 2011
S. Merchant, B. Lee, M. Nelson, T. Newsom-Davis, K. Naresh,

B. Gazzard, M. Bower
Clinical features and outcome in 61 patients with HIVassociated multicentric Castlemans disease.
2011
6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.
V Tittle, C Fernandez, A Scourfield, B Gazzard, M Bower and

M Nelson.
A comparison of inpatient admissions in 2005 and 2010

at a tertiary centre
HIV Medicine 2011, 12 (Suppl 1), 68.
J Krell, T Newsom-Davis, M Bower, J Stebbing and M

Nelson
Coinfection with hepatitis B virus does not increase the

risk of HIV-associated non-Hodgkin lymphoma
S Westrop, G DSouza, M Bower, B Gazzard, M Nelson and

N Imami
Algorithmic prediction for the identification of novel
HLA-B*2705-restricted HIV-1 CD8 T-cell epitopes:
assessment of epitope stability, affinity and specific
T-cell profile
A Scourfield, A Jackson, L Waters, J Dunning, S de Silva, N

Francis, P Holmes, M Nelson and M Bower.
An atypical presentation of Kaposis sarcoma.
D Awoyemi, B Gazzard, M Bower, S Yau and M Nelson

Antiretroviral drug dosing in renal impairment
HIV Medicine 2011, 12 (Suppl 1), 54
A Scourfield, L Waters, V Tittle, T Martin, N Rockwood, B

Gazzard, M Bower and M Nelson
Azathioprine use as a novel treatment for cryptococcal

immune reconstitution and inflammatory syndrome in
HIV
Byakika-Kibwika P, Lamorde M, Lwabi P, Nyakoojo WB,

Okaba-Kayom V, Mayanja-Kizza H, Boffito M, Katabira E,
Back D, Khoo S, Merry C
Cardiac Conduction Safety during Coadministration of

Artemether-Lumefantrine and Lopinavir/Ritonavir in
HIV-Infected Ugandan Adults
Chemother Res Pract. 2011;393976
M Alfa-Wali, T Allen-Mersh, A Antoniou, D Tait, T NewsomDavis, B Gazzard, M Nelson and M Bower
S Merchant, V Bradley, M Mak, B Gazzard, M Nelson, M

Bower and T Newsom-Davis
Demographics, histology and survival in HIV-associated

lung cancer
Mounier N, Bower M, Spina M, Besson C, Schiantarelli C, Re

A, Bonnet F, Hentrich M, Schommers P, Van Den Neste E,
Costagliola D, Borsatti E and Tirelli U.
Early determination of treatment sensitivity in HIVrelated Hodgkin lymphoma by FDG-PET/CT after two
cycles of ABVD chemotherapy
GECAT (European Cooperative Study Group on AIDS and

Tumors). Third international workshop on interim-PET in
lymphoma, Menton, France 2011
S Merchant, A Marouf, V Bradley, J Myers, T Newsom-Davis,
M Nelson, B Gazzard and M Bower.
Effect of raltegravir on rates of chemotherapy-induced
neutropenia in HIV lymphomas
R Robey, S Mletzko, M Bower, R Meys, M Boffito, M Nelson,S

Merchant, B Gazzard, C Boshoff and F Gotch
Ex-vivo recognition of late-lytic CD8 epitopes specific
for Kaposis sarcoma-associated herpesvirus (KSHV) by
HIV/KSHV-coinfected individuals
Merchant S, Marouf A, Hachach-Haram N, Nelson M, Bower

M and Newsom-Davis T
Histopathological trends in HIV-associated lung cancer
Lung Cancer 2011; 71(S1), 11
15
2011 continued
S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson,
M Shanyinde, K Cwynarski, R Marcus, J de Vos, AM Young,
M Tenant-Flowers, C Orkin, M Johnson, D Chilton, J
Gribben, M Bow
HIV Status Does Not Impact on Outcome in Patients with

Hodgkin Lymphoma Treated with ABVD Chemotherapy
in the HAART Era
Proc American Society of Haematology 2011.
Michael Furman, Pascual Balsalobre, Brady E. Beltran,

Michele Bibas, Mark Bower, Weina Chen, Silvia Montoto,
Roberto N. Miranda, Nahid M. Nanaji, Jose-Tomas
Navarro, Adam C. Seegmiller, Julie M. Vose and Jorge J
Castill
HIV-Associated Plasmablastic Lymphoma: A MultiInstitutional Study
Proc American Society of Haematology 2011.
E Page, M Bower, D Kaplan, J Daruich, L Kikuchi, M Marques

Molero, D Rimland, M Goetz, J Pineda8, K Marks, N Brau
and M Nelson
HIV-infected patients with hepatocellular carcinoma live

longer if they have undetectable HIV RNA.
HIV Medicine 2011, 12 (Suppl 1), 7. 2011
K Shahabuddin, R Mehta, S Graeme-Baker, H Gay, C Davies,

N Khan, F Kazmi, B Gazzard, M Bower and M Nelson.
Imaging of anorectal pathology by MR in people with
HIV infection
S Mletzko, A Kyriakou, R Robey, M Bower, M Nelson, S

Merchant, B Gazzard, C Boshoff and F Gotch
Bulteel N, Bower M, Gazzard B, Mandalia S, Nelson M

Is emtricitabine associated with reduced levels
of the M184V mutation when compared with
lamivudine?
13th European AIDS Conference, Belgrade 2011
L Baber, S Sonecha, S Mandalia, M Bower, B Gazzard and M

Nelson
Patients willingness to switch from a single-tablet
regimen (STR) to individual drugs as part of a potential
cost-saving strategy
Letang E, Lewis J, Bower M, Mosam A, Borok M, Naniche D,

Newsom-Davis T, Shaik F, Campbell T and Easterbrook P.
Predictors of paradoxical IRIS associated with Kaposis
sarcoma in Sub-Saharan Africa and the UK: Developing
a predictive score
18th conference on retroviruses and opportunistic infections

(CROI) 2011, 417.
Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, Baily
G, Brettle R, Gompels M, Johnson M, McCarron B, Ong E,
Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams
I, Gazzard B; NPMS-HHC Steering Group.
The cost-effectiveness of early access to HIV services
and starting cART in the UK 1996-2008.
PLoS One. 2011;6(12
B Lee, S Merchant, A Sita-Lumsden, B Gazzard, M Nelson

and M Bower
The incidence and correlates of paraneoplastic

syndromes in 62 HIV-positive patients with Hodgkins
Lymphoma.
Impaired dendritic cell (DC) function in Kaposis

sarcoma-associated herpesvirus (KSHV) infections.
K. Wheatley, J. Roe, M. Nelson, T. Newsom-Davis, B.

Gazzard, M. Bower.
S Westrop, D Lagos, M Bower, F Gotch, B Gazzard, C

Boshoff and N Imami
6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.
Increased incidence of multicentric Castlemans disease

in KSHV+ HIV-1+ individuals of Black African ethnicity
may result from the higher frequency of the TLR4 single
nucleotide polymorphism A299G.
The safety of Rituximab in HIV non-Hodgkin lymphoma

patients with low CD4 cell counts
J Roe, K Wheatley, T Kordbacheh, T Newsom-Davis, B

Gazzard, M Nelson and M Bower.
The safety of rituximab in patients with low CD4 cell

counts
Okusun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus

R, Virchis A, McNamara C, Bower M & Cwynarski K.
Haematologica
A Scourfield, T Martin, N Rockwood, L Waters, S de Silva, P

Holmes, M Bower, B Gazzard and M Nelson.
Interim FDG-PET predicts response and progression free

survival in patients with Hodgkin lymphoma and HIV
infection
Proc European Haematology Association. 2001 A774.
16
The use of faecal elastase to screen for pancreatic

insufficiency in HIV-infected individuals
A Scourfield, L Waters, T Martin, N Rockwood, M Bower, M

Nelson and B Gazzard.
Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns

B, Pillay D, Nelson M.
Antiviral Res. 2010 May;86(2):224-6
Will earlier diagnosis of HIV reduce the presentation of

serious opportunistic infections?
2010
Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K,
Sheedy B, Hingorani V, Raney A, Nguyen M, Nguyen T, Ong
V, Yeh LT, Quart B.
A Phase 2a randomized controlled trial of the short
term activity, safety and pharmacokinetics of a novel
NNRTI, RDEA806 in HIV-1 positive, antiretroviral-naive
subjects.
Antimicrob Agents Chemother. 2010 May 24.
Teague A, Scott C, Bower M, Gazzard B, Nelson M, Stebbing

J.
A single-center cohort experience of raltegravir in
salvage patients failing therapy.
J Acquir Immune Defic Syndr. 2010 Apr;53(5):666-7
Clinical outcome in resistant HIV-2 infection treated

with raltegravir and maraviroc.
Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J,

Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M,
Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker
A, Delpech V; on behalf of the UK Collaborative HIV Cohort
(UK CHIC) Study Group.
Data linkage reduces loss to follow-up in an
observational HIV cohort study.
J Clin Epidemiol. 2010 Mar 26.
Moyle G, Demasi R, Hill A.
Does earlier HIV RNA suppression provide long-term

benefits?
AIDS 2010;24:1591-3
Falutz J, Mamputu J-C, Potvin D, Moyle G, Soulban G,

Loughrey H, Marsolais C, Turner R, Grinspoon S.
Effects of Tesamorelin (TH9507), a Growth HormoneReleasing Factor Analog, in Human Immunodeficiency

Virus-Infected Patients with Excess Abdominal
J Clin Endocrinol Metab 16 June 2010,
Gazzard B, Balkin A, Hill A.
Analysis of neuropsychiatric adverse events during

clinical trials of efavirenz in antiretroviral-naive patients:
a systematic review.
AIDS Rev. 2010 Apr-Jun;12(2):67-75.
Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C,

Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R,
Agarwal K, Sabin C, Deacon-Adams C; BHIVA Viral Hepatitis
Working Group
British HIV Association guidelines for the management
of coinfection with HIV-1 and hepatitis B or C virus
2010
HIV Med. 2010 Jan;11(1):1-30
Cooper V, Moyle G, Fisher M, Reilly G, JEwan J, Liu H.C,

Horne R for the SWEET group UK
Changes in adherence and patients perceptions
of treatment in a 48 weekrandomised study of
continuation of zidovudine/lamividine or switch to
tenofovir DF/emtricitabine, each with efavirenz.
AIDS Care 2010: in press
Page EE, Cox A, Atkins M, Nelson MR.
Clearance of hepatitis C virus RNA from serum in HIV/

hepatitis C virus coinfection indicates eradication from
peripheral blood mononuclear cells
Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M,

Michaud SE, Berger D, Somero M, Moyle G, Brown S,
Martorell C, Turner R, Grinspoon S.
Effects of Tesamorelin, a Growth Hormone-Releasing

Factor, in HIV-Infected Patients With Abdominal Fat
Accumulation: A Randomized Placebo-Controlled Trial
With a Safety Extension.
Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo

SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT,
Vanveggel S, Boven K; TMC278-C204 Study Group.
Efficacy and safety of TMC278 in antiretroviralnaive HIV-1 patients: week 96 results of a phase IIb
randomized trial.
AIDS. 2010 Jan 2;24(1):55-65.
On I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B,

Nelson M, Stebbing J.
Epidemiology of herpes simplex virus types 2 and 1
amongst men who have sex with men (MSM) attending
sexual health clinics in England and Wales: implications
for HIV prevention and management
Eurosurveillance in press.
AIDS. 2010 Jun 1;24(9):1267-71
17
2010 continued
R Jones, A Menon-Johansson, AM Waters, AK Sullivan
eTriage a novle, web-based triage and booking

service: enabling timely access to sexual health clinics
Int J STD & AIDS 2010; 21:30-33.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara

C, Orkin C, Nelson M, Johnson M, Bower M, Cwynarski AK.
Excellent immunological recovery following CODOX-M/
IVAC, an effective intensive chemotherapy for HIVassociated Burkitts lymphoma.
AIDS. 2010 Mar 27;24(6):851-6
Ridha E, Cookson H, Devitt E, Nelson M.
Febrile neutropenia in a HIV positive individual postchemotherapy

J Clin Virol. 2010 May;48(1):2-5. Epub 2010 Feb 18
Alfa-Wali A, Antoniou A, Allen-Mersh T, Tekkis P, Tate D, Sita

Lumsden A, Nelson M & Bower M
HIV-associated colorectal cancer and the immunological

effects of treatment
HIV Medicine 2010, 11 (suppl 1), 58.
Wilson J, Devitt E, Rampling T, Namulema E, Bower M &

Nelson M
Increasing prevalence of pulmonary tuberculosis in HIVinfected individuals in Kampala, Uganda.

HIV Medicine 2010, 11 (suppl 1),
Menon-Johansson A.S, Cohen C.E., Jones R., Nwokolo N.,

McOwan A., Barton S.E. & Sullivan A.K
Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM,

Dewolf F, Nelson M, Geretti AM, Larder BA
Modelling response to HIV therapy without a genotype:

an argument for viral load monitoring in resourcelimited settings
J Antimicrob Chemother. 2010 Apr;65(4):605-7
McClean H, CA Carne, AK Sullivan, A Menon-Johansson, R

Gokhale, G Sethi, AG Mammen-Tobin, D Daniels.
National Audit of Asymptomatic Screening in UK
Genitourinary Medicine Clinics: Clinic Policies Audit.
Int J STD & AIDS in press
Rashid T, Meryon I, Mandalia S, Waters L, Devitt E, Bower M,

Jones R & Nelson M
No association of vitamin D levels with individual
antiretroviral agents, duration of HIV infection,
alkaline phosphatise levels or bone mineral density
findings
HIV Medicine 2010, 11 (suppl 1), 34
Bower M, Montoto S, Cwynarski K, Sita Lumsden A, Rajab R,

Okosum J, Orkin C, Nelson M, Isaacson P, Calaminici M &
Naresh K
Non-germinal centre subtype of AIDS-related diffuse
large B-cell lymphomas associated with improved
survival.
Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali

F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF,
Gibb DM, Khoo S; DART Trial Team
Pharmacokinetics of lopinavir-ritonavir with and
without nonnucleoside reverse transcriptase inhibitors
in Ugandan HIV-infected adults.
Interventions to increase access to STI services: A study

of EnglandsHigh Impact Changes across three central
London clinics
Antimicrob Agents Chemother. 2010 Jul;54(7):2965-73.
Yilmaz S, Boffito M, Collot-Teixeira S, De Lorenzo F, Waters L,

Fletcher C, Back D, Pozniak A, Gazzard B, McGregor JL.
Positive and negative drug selection pressures on the

N3481 connection domain mutation: new insights from
in vivo data
STI 2010 in press
Investigation of low-dose ritonavir on human peripheral

blood mononuclear cells using gene expression whole
genome microarrays.
Price H, Asboe D, Gazzard B, Fearnhill E. Pillay D, Dunn

D: UK Collaborative Group on HIV Drug Resistance; UK
Collaborative HIV Cohort Study
Anitfir Ther. 2010: 15(2): 203-11.
Genomics. 2010 Jul;96(1):57-65. Epub 2010 Mar 28. 2010
Willis J, Jones R, Nwokolo N and Levy J
UK Collaborative Group on HIV Drug Resistance; UK CHIC

Study Group
BMJ 2010;340:b5027
Long-term probability of detecting drug-resistant HIV

in treatment-naive patients initiating combination
antiretroviral therapy
Protein and Creatine Supplements and Misdiagnosis of

Kidney Disease
Clin Infect Dis. 2010 May 1;50(9):1275-85.
18
Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D,

Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses
MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.
Randomized Comparison of Renal Effects, Efficacy, and
Safety With Once-Daily Abacavir/Lamivudine Versus
Tenofovir/Emtricitabine, Administered With Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week
Results From the ASSERT Study
J Acquir Immune Defic Syndr. 2010 Apr 24.
Jones R, Brown D, Nelson M, Low E, Bhagani S, Atkins M,

Danta M, Dusheiko G, Pybus O, Asboe D.
Re-emergent hepatitis C viremia after apparent

clearance in HIV-positive men who have sex with men:
reinfection or late recurrence?
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):547-50. No

abstract available. Erratum in: J Acquir Immune Defic Syndr.
2010 May 1;54(1):112
Williams J, Jones R, Nelson M, Barlow S, Short D, Savage P,
Seckl M, Schmidt P & Bower M.
Six cases of gestational trophoblastic tumours in
women living with HIV.
Scourfield A, Waters L, Brown G, Bower M & Nelson M.

Spectrum of neurological disease in patients
with discordant HIV-1 RNA levels in plasma and
cerebrospinal fluid.
HIV Medicine 2010, 11 (suppl 1), 34-5.
HIV-CAUSAL Collaboration
The effect of combined antiretroviral therapy on the

overall mortality of HIV-infected individuals
AIDS. 2010 Jan 2;24(1):123-37
Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.
The effect of tenofovir disoproxil fumarate on wholebody insulin sensitivity, lipids and adipokines in healthy
volunteers
Antivir Ther. 2010;15:227-33.
on I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B,

Nelson M, Stebbing J.
The frequency and reasons for antiretroviral switching
with specific antiretroviral associations: the SWITCH
study.
Antiviral Res. 2010 May;86(2):227-9
Dunn D, von Wyl V, Price H, Asboe D.
The impact of the 0-0 cell on measures of amino acid

covariation
Arribas JR, Horban A, Gerstoft J, Ftkenheuer G, Nelson

M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T,
Moecklinghoff C.
The MONET trial: darunavir/ritonavir with or without

nucleoside analogues, for patients with HIV RNA below
50 copies/ml
AIDS. 2010 Jan 16;24(2):223-30
Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet

M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.
Treatment of acute HCV infection in HIV-positive
patients: experience from a multicentre European
cohort
Antivir Ther. 2010;15(2):267-79
Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J,

Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter
K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C,
Nelson M, Rice B, Phillips A; UK Collaborative HIV Cohort
(CHIC) Study and the Health Protection Agency
Trends over calendar time in antiretroviral treatment
success and failure in HIV clinic populations
HIV Med. 2010 Aug;11(7):432-8
Hardy WD, Gulick RM, Mayer H, Ftkenheuer G, Nelson M,

Heera J, Rajicic N, Goodrich J.
Two-Year Safety and Virologic Efficacy of Maraviroc in

Treatment-Experienced Patients With CCR5-Tropic HIV-1
Infection: 96-Week Combined Analysis of MOTIVATE 1
and 2.
J Acquir Immune Defic Syndr. 2010 Aug 11
Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D
Unselected hepatitis C screening of men who have sex

with men attending sexual health clinics
J Infect. 2010 May;60(5):351-3. Epub 2010 Feb 12.PMID:
20153770
Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A,

Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C,
Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E,
Dally L, Gotch F, Walker B, Gilmour J, Hayes P
Viral inhibition assay: a CD8 T cell neutralization assay
for use in clinical trials of HIV-1 vaccine candidates.
J Infect Dis. 2010 Mar;201(5):720-9 2010
Brown G, Scott C, Teague A, Bower M, Gazzard B

& Nelson M
Virological efficacy of darunavir/ritonavir monotherapy

in clinical practice
HIV Medicine 2010, 11 (suppl 1), 24
AIDS. 2010 Jan 2;24(1):159-60. No abstract available
19
2009
Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR,
Mandalia S, Bower M, Gazzard B, Nelson M
A Meta-analysis of Transient Elastography for the

Detection of Hepatic Fibrosis
J Clin Gastroenterol. 2009 Sep 9.
Stebbing J, Scourfield A, Koh G, Taylor C, Taylor S, Wilkins E,

Gazzard B, Nelson M, Jones R.
Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ,

Sax P
Antiretroviral therapy update from the 48th ICAAC/46th

IDSA annual meeting
AIDS Read. 2009;19:22-31.
Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF,
Moyle GJ, Jackson AA, Gazzard BG.
Antiretroviral therapy with or without protease
inhibitors impairs postprandial TAG hydrolysis in HIVinfected men.
A multicentre cohort experience with double-boosted

protease inhibitors.
Br J Nutr. 2009 Jun 1:1-9.
Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M,

Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G for the SWEET
(Simplification With Easier Emtricitabine Tenofovir) group
UK
Burkitts non-Hodgkin lymphoa presenting as an

isolated Bells palsy in HIV-positive patients
J Antimicrob Chemother. 2009 Aug;64(2):434-5.
A Randomized Comparative Trial of Continued

Zidovudine/Lamivudine or Replacement With Tenofovir
Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated
HIV-1-Infected Individuals
Woodcock H, Holmes P, Powles S, Dunning J, Bower M &

Nelson M.
HIV Medicine 2009, 10 (Suppl1), 23 2009
Scott C, Azwa A, Cohen C, McIntyre M, Desmond N

Catscratch disease: a diagnostic conundrum
Int J STD AIDS. 2009 Aug; 20(8) 585-6
Journal of Acquired Immune Deficiency Syndromes.

2009:51:562-568
Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey

D, Skoutelis A, Goetz MB, Phillips AN
HIV Clin Trials. 2009 Sep-Oct;10(5):289-98.
Activation and coagulation biomarkers are independent

predictors of the development of opportunistic disease
in patients with HIV infection.
J Infect Dis. 2009 Sep 15;200(6):973-83.
Holmes P, Low E, Bower M, Anderson M & Nelson M.
Acute hepatitis C is not associated with abnormal

fibroscan readings
HIV Medicine 2009, 10 (Suppl1), 30
Ng SC, Gazzard B.
Advances in sexually transmitted infections of the

gastrointestinal tract
Nat Rev Gastroenterol Hepatol. 2009 Aug 25
Powles S, Weir J, Francis N, Newsom-Davis T, Crook T,

Boffito M, Nelson M & Bower M.
AIDS Kaposis sarcoma: outcomes in 254 consecutive

patients diagnosed in modern times
HIV Medicine 2009, 10 (Suppl1), 10.
Causes and consequences of incomplete HIV RNA

suppression in clinical trials.
Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips

AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B,
Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels
M, Sabin CA
CD4 counts and the risk of systemic non-Hodgkins
lymphoma in individuals with HIV in the UK.
Haematologica. 2009 Jun;94(6):875-80
Teague A, Scott C, Bower M, Gazzard B & Nelson M.
Clinical experience of raltegravir in salvage patients

failing therapy, 48-week data
Moyle G, Rajicic N, Goodrich J, Mayer H, Valdez H.
Concurrent use of statins does not influence efficacy

of maraviroc in Maraviroc versus Optimized Therapy in
Viremic Antiretroviral Treatment-Experienced Patients 1
and 2 trials
AIDS 2009: 23:1613.
Walmsley S, Wilkin T, Moyle G
Antiretroviral rounds. Too many options?

AIDS Clin Care. 2009;21:13-5.
20
Panos G, Farouk L, Stebbing J, Holmes P, Valero S, Randell P,

Bower M, Gazzard B, Anderson M, Nelson M
Cryptogenic pseudocirrhosis: a new clinical syndrome
of noncirrhotic portal hypertension (unassociated with
advanced fibrosis) that can be detected by transient
elastography in patients with HIV
J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):525-7
Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P,
Gazzard B, Nelson M, Stebbing J.
Cytokine changes during rituximab therapy in HIVassociated multicentric Castleman disease.

Blood. 2009 May 7;113(19):4521-4.
Scott C, Teague A, Bower M, Gazzard B & Nelson M
Darunavir/ritonavir once daily: a single-centre cohort

experience
Soodalter J, Sousa M, Boffito M
Drug-drug interactions involving new antiretroviral

drugs and drug classes.
Curr Opin Infect Dis. 2009 Feb;22(1):18-27.
ScourfieldA, Waters L, Randell PA, McCormick K, Armenis K,

Bower M & Nelson M
Effect of raltegravir on ALT in subjects coinfected with
HIV and hepatitis C
Arasth K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D,

Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F.
Efficacy and safety of darunavir/ritonavir in treatmentexperienced HIV type-1 patients in the POWER 1, 2 and
3 trials at week 96.
Antivir Ther. 2009;14(6):859-64.
Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson

M, Bower M & Cwynarski K.
Excellent immunological recovery following the
intensive chemotherapy CODOX-M IVAC, an effective
therapy for HIV associated Burkitts lymphoma.
Dunning J, Myers J, Holmes P, Stuart-Buttle C, Bower M &

Nelson M.
Experience with ritonavir/atazanavir in HIV-positive
antiretroviral naive individuals commencing therapy.
Hill A, Sawyer W, Gazzard B.
Fat: A Pooled Analysis of Two Multicenter, Double-Blind

Placebo-Controlled Phase 3 Trials with Safety Extension
Data
HIV Clin Trials. 2009 Jan-Feb;10(1):1-12.
Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M,

ODoherty M & Bower M.
FDG-PET/CT imaging in the management of HIVassociated multicentric Castlemans disease
Eur J Nucl Med Imaging. 2009, 36: 648-52
Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V,

Bower M, Dezube BJ
Gastroenteropancreatic Neuroendocrine Tumors in
Patients With HIV Infection: A Trans-Atlantic Series.
Am J Med Sci. 2009 Jan;337(1):1-4.
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M,

Gazzard B, Mandelia S, Moller H & Bower M
Highly active antiretroviral therapy and the incidence of

Non-AIDS defining cancers in people with HIV infection
J Clin Oncol. 2009 Feb 20;27(6):884-90.
Pozniak A, Mller L, Salgo M, Jones JK, Larson P, Tweats D.
Price H, Sullivan AK
AIDS Res Ther. 2009 Aug 6;6:18.
Int J STD AIDS. 2009 Jan;20(1):56-7.
Elevated ethyl methanesulfonate (EMS) in nelfinavir

mesylate (Viracept, Roche): overview.
Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM &

Goodier MR.
Elevated plasma lipopolysaccharide is not sufficient

to drive natural killer cell activation in HIV-1 infected
individuals.
AIDS 2009, 23: 29-34.
HIV opt out increases the offer and uptake of HIV tests
in a GUM clinic
Gazzard B.
HIV testing in the UK
Lancet. 2009 Aug 1;374(9687):377

Vogel M, Nelson M.
HIV/HCV-coinfection: which role can new antiretrovirals

such as integrase inhibitors play?
Eur J Med Res. 2009 Nov 24;14 Suppl 3:36-42. Review.
21
2009 continued
Herasimtschuk A, Nelson M, Moyle G, Bower M & Imani N
Impact of recombinant human growth hormone on

T-cell phenotype and function in vitro and in vivo during
treated HIV-1 infection.
Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA,

Moyle G, Linney A, Reilly G, Edwards S.
Improvements in cheek volume in lipoatrophic

individuals switching away from thymidine nucleoside
reverse transcriptase inhibitors
HIV Medicine 2009;10:351-5
Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy

R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT
SMART Study Group.
Interruption of antiretroviral therapy is associated with

increased plasma cystatin C
AIDS. 2009 Jan 2;23(1):71-82.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C,

Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay
D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips
A, Sabin C; on behalf of the UK Collaborative HIV Cohort
(CHIC) Study
Is 1 Alanine Transaminase >200 IU Enough to Define an

Alanine Transaminase Flare in HIV-Infected Populations?
A New Definition Derived From a Large Cohort Study.
Crook T, Syed N, Papoudou-Bai A, Stebbing J, Naresh K,

Nelson M, Hatzimichael E & Bower M
Methylation reversal in high grade B-cell lymphoma

cell lines identifies novel epigenetic changes conserved
between immunocompetent and HIV-positive hosts and
others specific to HIV-associated lymphomas.
Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P,

Patterson S.
Monocyte-derived dendritic cells from HIV type

1-infected individuals show reduced ability to stimulate
T cells and have altered production of interleukin (IL)-12
and IL-10.
J Infect Dis. 2009 Jun 15;199(12):1862-71.
Dunning J, Nelson M.
Novel strategies to treat antiretroviral-naive HIVinfected patients.

J Antimicrob Chemother. 2009 Oct;64(4):674-9.
22
Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti

I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV,
Lavreys L
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir
in treatment-naive, HIV-1-infected patients: 96-week
analysis.
AIDS. 2009 Aug 24;23(13):1679-88.
Sekar V, Lefebvre E, Marin K, De Pauw M, Vangeneugden T,

Pozniak A, Hoetelmans RM.
Pharmacokinetic interaction between nevirapine and
darunavir with low-dose ritonavir in HIV-1-infected
patients.
Br J Clin Pharmacol. 2009 Jul;68(1):116-9.
Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor

J, Waters L, Asboe D, Gazzard B, Pozniak A.
Pharmacokinetics and Safety of Etravirine Administered

Once or Twice Daily After 2 Weeks Treatment With
Efavirenz in Healthy Volunteers.
J Acquir Immune Defic Syndr. 2009 Jul 17
Coyne KM, Pozniak AL, Lamorde M, Boffito M
Pharmacology of second-line antituberculosis drugs

and potential for interactions with antiretroviral agents
AIDS. 2009 Feb 20;23(4):437-46.
Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G,

Khoo S, Pozniak A, Aarons L.
Population pharmacokinetics of ritonavir-boosted
atazanavir in HIV-infected patients and healthy
volunteers.
J Antimicrob Chemother. 2009 Jun;63(6):1233-43. Epub

2009 Mar 28
Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks
CB, Klein CE, Chiu YL, King MS, Bernstein BM.
Predictors of loss of virologic response in subjects who
simplified to lopinavir/ritonavir monotherapy from
lopinavir/ritonavir plus zidovudine/lamivudine.
AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75.
De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B,

McGregor JL, Shotliff K, Xiao H.
Prevention of atherosclerosis in patients living with HIV.

Vasc Health Risk Manag. 2009;5(1):287-300.
Moyle G, Dejesus E, Boffito M, Wong RS, Gibney C, Badel

K, Macfarland R, Calandra G, Bridger G, Becker S; X4
Antagonist Concept Trial Study Team.
Proof of Activity with AMD11070, an Orally
Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1.
Clin Infect Dis. 2009;48:798-805.
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett

PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M,
Cameron DW, Brown ST; OPTIMA Team1.
Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH,

Lou Y, Yuen GJ, Min SS, Guerini EM.
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9.
Antimicrob Agents Chemother. 2009;53:1532-8
Quality of life of patients with advanced HIV/AIDS:

measuring the impact of both AIDS-defining events and
non-AIDS serious adverse events.
Annan NT, Sullivan AK, Nori A, Naydenova P, Alexander

S, McKenna A, Azadian B, Mandalia S, Rossi M, Ward H,
Nwokolo N.
Rectal Chlamydia a reservoir of undiagnosed infection

in men who have sex with men.
Sex Transm Infect 2009; 85:176-9.
Tan LK, Gilleece Y, Mandalia S, Murungi A, Grover D, Fisher

M, Atkins M, Nelson M.
Steady state pharmacokinetics of plasma abacavir and

intracellular carbovir triphosphate following abacavir
600mg once daily and 300g twice daily in HIV-infected
subjects
Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH,

Lou Y, Yuen GJ, Min SS, Guerini EM
Steady-state pharmacokinetics of abacavir in plasma
and intracellular carbovir triphosphate following
administration of abacavir at 600 milligrams once
daily and 300 milligrams twice daily in human
immunodeficiency virus-infected subjects.
Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8
Reduced glomerular filtration rate but sustained

virologic response in HIV/hepatitis B co-infected
individuals on long-term tenofovir
Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W,

Pozniak A, Taylor G, Asboe D, Lyall H, Shaw A, Kapembwa M
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ,
Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft
A; Nevirapine Toxicity Multicohort Collaboration.
AIDS. 2009 Jan 28;23(3):434-5. No abstract available
J Viral Hepat. 2009 Jul;16(7):471-8.
Risk factors for treatment-limiting toxicities in

patients starting nevirapine-containing antiretroviral
therapy.
AIDS. 2009 Aug 24;23(13):1689-99
Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ,

Sax PE
Select updates from the 16th CROI: treatment-related
cardiovascular risk, pharmacokinetic issues, and
interleukin-2 use
AIDS Read. 2009;19:158-60.
Coyne KM, Banks A, Heggie C, Scott CJ, Grover D, Evans C,

Mandalia S, McLean KA, Cohen CE
Sexual health of adults working in pornographic films
Int J STD AIDS. 2009 Jul;20(7):508-9
Teague A, Scott C, Youngstein T, Bower M, Gazzard B &

Nelson M.
Switching to raltegravir: a successful strategy in

treatment-experienced patients with toxicity? 48 week
data
Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson

R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher
M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK
Collaborative HIV Cohort (CHIC) Study.
The associations between age and the development of
laboratory abnormalities and treatment discontinuation
for reasons other than virological failure in the first year
of highly active antiretroviral therapy.
HIV Med. 2009 Jan;10(1):35-43. Epub 2008 Nov 10.
Bower M, Weir J, Francis N, Newsom-Davis T, Powles S,

Crook T, Boffito M, Gazzard B, Nelson M
Barton S
Sexually transmitted diseases by Dr Lisa Marr

AIDS Care. Vol 21. No. 4 April 2009
The effect of HAART in 254 consecutive patients with

AIDS-related Kaposis sarcoma.
AIDS. 2009, 23(13):1701-6.
Arasth K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van

Heeswijk R, de Bthune MP, Peeters M, Woodfall B.
Short-term randomized proof-of-principle trial of
TMC278 in patients with HIV type-1 who have
previously failed antiretroviral therapy.
Antivir Ther. 2009;14(5):713-22.
Successful use of darunavir, etravirine, enfuvirtide

and tenofovir/emtricitabine in pregnant woman with
multiclass HIV resistance
Coyne K, Mandalia S, McCullough S, Catalan J, Noestlinger

C, Colebunders R, Asboe D
The International Index of Erectile Function:
development of an adapted tool for use in HIV-positive
men who have sex with men.
J Sex Med. 2010 Feb;7(2 Pt 1):769-74. Epub 2009 Nov 12
23
2009 continued
Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG,
Stebbing J.
The Nucleoside Backbone Affects Durability of
Efavirenz- or Nevirapine-Based Highly Active
Antiretroviral Therapy in Antiretroviral-Naive
Individuals
J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6.

Stebbing J, Wong N, Tan L, Scourfield A, Jiao L, Shousha S,
Grover D, Bower M, Nelson M
The relationship between prolonged antiretroviral
therapy and cryptogenic liver disease
J Acquir Immune Defic Syndr. 2009 Apr 1;50(5):554-6.

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S,
Nelson M, Gazzard B, Bower M.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J,

Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M,
Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK
Collaborative HIV Cohort Study.
Virological response to initial antiretroviral regimens
containing abacavir or tenofovir.
J Infect Dis. 2009 Sep 1;200(5):710-4.
2008
Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles
C, Kew A, Nelson M, Kanfer E.
A long-term durable remission with high-dose therapy
and autologous stem cell transplant for stage IVB HIVassociated Hodgkins disease
AIDS. 2008 Feb 19;22(4):539-40
The role of immune suppression and HHV-8 in the

increasing incidence of HIV-associated multicentric
Castlemans disease.
Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.
Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M,

Gazzard B & Stebbing J.
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9
Ann Oncol. 2009, 20:775-9.
Thyroid dysfunction and relationship to antiretroviral

therapy in HIV-positive individuals in the HAART era.
J Acquir Immune Defic Syndr. 2009, 50: 113-114.
Westrop SJ, Qazi NA, Pido-Lopez J, Nelson MR, Gazzard B,

Gotch FM, Imami N.
Transient nature of long-term nonprogression and
broad virus-specific proliferative T-cell responses with
sustained thymic output in HIV-1 controllers.
PLoS One. 2009;4(5):e5474
Vogel M, Page E, Nelson M, Rockstroh JK.
A novel probe drug interaction study to investigate the

effect of selected antiretroviral combinations on the
pharmacokinetics of a single oral dose of maraviroc in
HIV-positive subjects.
Boffito M, Abel S.
A review of the clinical pharmacology of maraviroc.

Introduction
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:1-4
Scott C, Jogiya R, Teague A, Bower M, Gazzard B

& Nelson M
A single centre experience with darunavir/ritonavir

(DRV/r) (600mg/100mg) and optimised background
regimen in clinical practice
HIV Medicine 2008, 9 (Suppl 1): 14 2008
Treatment of acute hepatitis C in HIV-positive

individuals: what are the challenges?
Scott C, Staughton RC, Bunker CJ, Asboe D
A. Hughes, E. Jungmann, S. Manney, L. Muromba, N.

Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K.
Sullivan.
Int J STD AIDS. 2008 Jul;19(7):493-5
J HIV Ther. 2009 Mar;14(1):8-12. Review
United Kingdom acquisition of HIV infection in African

residents in London: more than previously thought.
AIDS 2009; 23:262-6.
Stebbing J, Asghar AK, Holmes P, Bower M, Isenman HL &

Nelson M. J
Use of ezetimibe during HIV infection
Acne vulgaris and acne rosacea as part of immune

reconstitution disease in HIV-1 infected patients starting
antiretroviral therapy.
FM Burns, R Arthur, A Johnson, J Nazroo, K Fenton; on

behalf of the SONHIA collaboration group J. Ainsworth, J.
Anderson, M. Chikohora, A. Fakoya, I.Fakoya, A. Hughes,
E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N.
Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K. Sullivan
Acquisition of HIV infection in Africans resident in
London: how much and how to assess
AIDS 2008; in press
Antimicrob Chemother. 2009, 6: 43-52.
24
Di Lorenzo G, Kreuter A, Di Trolio R, Guarini A, Romano C,

Montesarchio V, Brockmeyer NH, De Placido S, Bower M,
Dezube BJ
Steel A, John L, Shamji MH, Henderson DC, Gotch FM,

Gazzard BG, Kelleher P.
J Invest Dermatol. 2008 Jan 10
HIV Med. 2008 Feb;9(2):118-25
Activity and Safety of Pegylated Liposomal Doxorubicin

as First-Line Therapy in the Treatment of Non-Visceral
Classic Kaposis Sarcoma: A Multicenter Study
Stebbing J, Powles T, Bower M
AIDS-associated Kaposis sarcoma associated with a low

viral load and a high CD4 cell count
AIDS. 2008; 22(4):551-2
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T,

Leen C, Schwenk A, Johnson M, Anderson J, Gilson R,
Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay
D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV
Cohort (UK CHIC) Study
Are previous treatment interruptions associated
with higher viral rebound rates in patients with viral
suppression?
AIDS. 2008 Jan 30;22(3):349-56.
J. Krell, M. Tuthill, V. Campbell, M. Nelson, P. Holmes, T.

Powles, J. Stebbing, M. Bower
Cellular immunity following chemotherapy for systemic

AIDS related non Hodgkins lymphoma (NHL)
HIV Medicine 2008, 9 (Suppl 1): 24. 2008
Teague A, Scott C, Youngstein T, Bower M, Gazzard B &

Nelson M
Clinical experience with raltegravir (MK-0518 or

Isentress), with an optimised background regimen in
highly treatment experienced patients
HIV Medicine 2008, 9 (Suppl 1): 17.
Holmes P, Nelson M, Bower M, Gazzard B & Barton S.
Coyne KM, BartonSE, Smith NA, Cohen CE
Azithromycin without a prescription increases access

and choice for patients
Int. J. STD & AIDS 2008;19:870
Bower M, Collins S, Cottrill C, Cwynarski K, Montoto

S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales
N & Webb A on behalf of the AIDS malignancy
subcommittee
British HIV association guidelines for HIV-associated

malignancies 2008.
HIV Med 2008, 9: 336-388 2008
Coding and the clinician.

Daniels RH, Gazzard BG, Holmes P, Scourfield A, Bower M,
Nelson M
Comparing the efficacy of Truvada and Kivexa
combination therapy in HAART-naive individuals with
different viral loads.
Journal of the International AIDS Society 2008, 11 (Suppl
1):P14 (10November2008)
Gazzard BG.
Controversies in current treatment guidelines.
Gazzard BG; BHIVA Treatment Guidelines Writing Group

British HIV Association Guidelines for the treatment
of HIV-1-infected adults with antiretroviral therapy
2008.
HIV Med. 2008 Oct;9(8):563-608.
Stebbing J, Wood C, Atkins M, Bukowski R, Litwin S, Bower

M, Parsa A, Levitsky H
Cancer vaccines: Clinical development challenges and
proposed regulatory approaches for patient access to
promising treatments
Cancer. 2008;112(5):955-961
CD38 expression on CD8 T cells has a weak association

with CD4 T-cell recovery and is a poor marker of viral
replication in HIV-1-infected patients on antiretroviral
therapy
J HIV Ther. 2008 Mar;13(1):1-3.
Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A,

Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, PerezElias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van
Craenenbroeck E, Bacheler L.
Determination of clinically relevant cutoffs for HIV-1
phenotypic resistance estimates through a combined
analysis of clinical trial and cohort data.
J Acquir Immune Defic Syndr. 2008 May 1;48(1):26-34.
Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A,

van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD;
EuroSIDA Study Group.
Does less frequent routine monitoring of patients on
a stable, fully suppressed cART regimen lead to an
increased risk of treatment failure?
AIDS. 2008 Nov 12;22(17):2381-90.
25
2008 continued
Mihailidis C, Dunn D, Pillay D, Pozniak A
Effect of isolated V118I mutation in reverse

transcriptase on response to first-line antiretroviral
therapy
AIDS. 2008 Jan 30;22(3):427-30
Rosignoli G, Liptrott N, Imani N, Bower M, Gotch F

& Owen A
Effect of PD1.3 single nucleotide polymorphism on CD4

and CD3 T cell counts in HAART-treated chronic HIV-1+
patients.
Schller-Gyre M, Boffito M, Pozniak AL, Leemans R, Kakuda

TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K,
Hoetelmans RM.
Scott C, Khatib N, Bower M, Gazzard BG, Nelson M.
Etravirine use in clinical practice: 48-week data from a

single centre cohort.
Journal of the International AIDS Society 2008, 11(Suppl
1):P49 (10November2008)
Clumeck N, Pozniak A, Raffi F; EACS Executive Committee.
European AIDS Clinical Society (EACS) guidelines for

the clinical management and treatment of HIV-infected
adults
HIV Med. 2008 Feb;9(2):65-71
Asghar AK, Bower M, Holmes P, Gazzard BG, Isenman H,

Nelson M
Ezetimibe as lipid-lowering therapy for patients
receiving HAART.

1):P248 (10November2008)
Effects of different meal compositions and fasted state

on the oral bioavailability of etravirine.
Burton C, Eccles-James I, Nelson M, Bower M, Gotch F &

Imani N
Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS,

Imami N.
HIV Medicine 2008, 9 (Suppl 1): 41
Pharmacotherapy. 2008 Oct;28(10):1215-22.
Effects of recombinant human growth hormone on HIV1-specific T-cell responses, thymic output and proviral
DNA in patients on HAART: 48-week follow-up
J Immune Based Ther Vaccines. 2008; 6:7
Pessa MG, Gazzard B, Huang AK, Brando-Mello CE,

Cassetti I, Mendes-Corra MC, Soriano V, Phiri P, Hall A,
Brett-Smith H.
Efficacy and safety of entecavir for chronic HBV in HIV/

HBV coinfected patients receiving lamivudine as part of
antiretroviral therapy.
AIDS. 2008 Sep 12;22(14):1779-87.
Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D,

Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V
Functional and phenotypic profiling of suppressive

regulatory T cells in a cohort of HIV-1 Infected
individuals.
Macdonald DC, Nelson M, Bower M, Powles T.
Hepatocellular carcinoma, human immunodeficiency

virus and viral hepatitis in the HAART era.
World J Gastroenterol. 2008 Mar 21;14(11):1657-1663
Moyle G, Randell P
HIV and Cardiovascular risk
Clinical Medicine 2008;8:315-8.

Harania RS, Karuru J, Nelson M, Stebbing J.
HIV, hepatitis B and hepatitis C coinfection in Kenya

AIDS. 2008 Jun 19;22(10):1221-2.
Efficacy and tolerability of long-term efavirenz plus

nucleoside reverse transcriptase inhibitors for HIV-1
infection
Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M,

Dezube BJ
Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ.
Barber TJ, Menon-Johanson A, Barton S
PLoS Med. 2008 Mar 18;5(3):e50.
Br J Gen Pract. 2008 May: 58 (550): 365
AIDS. 2008 Jan 11;22(2):275-9
Episodic sexual transmission of HIV revealed by

molecular phylodynamics.
26
HIV-associated multicentric Castlemans disease

Am J Hematol. 2008; 83(6):498-503
How can we remove barriers to HIV testing outside of

GUM setting?
Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Stebbing

J, Powles T, Pantanowitz L
Naresh KN, Rice AJ, Bower M.
Clin Genitourin Cancer. 2008, 6(2):86-90
Am J Surg Pathol. 2008 Jul;32(7):1006-12
Human immunodeficiency virus-associated renal cell

carcinoma: a transatlantic case series.
Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes

P, Ozzard A, Nelson M, Gazzard B, Powles T
Immunological recovery in survivors following
chemotherapy for AIDS related non Hodgkins
lymphoma.
Blood. 2008 Jan 2;
Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P,

Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I,
Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study
group.
Impact of reverse transcriptase resistance on the
efficacy of TMC125 (etravirine) with two nucleoside
reverse transcriptase inhibitors in protease inhibitornave, nonnucleoside reverse transcriptase inhibitorexperienced patients: study TMC125-C227.
HIV Med. 2008 Nov;9(10):883-96
Strategies for Management of Antiretroviral Therapy

(SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W,
Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN
Inferior clinical outcome of the CD4+ cell count-guided

antiretroviral treatment interruption strategy in the
SMART study: role of CD4+ Cell counts and HIV RNA
levels during follow-up.
J Infect Dis. 2008 Apr 15;197(8):1145-55
Scott C, Grover D, Nelson M.
Is there a role for etravirine in patients with

Nonnucleoside reverse transcriptase inhibitor
resistance?
AIDS. 2008 May 11;22(8):989-90.
Asghar A, Bower M, Gazzard B, Holmes P, Isenman H &

Nelson M.
Lipid lowering effect of ezetimibe in patients with
HAART-associated dyslipidaemias
HIV Medicine 2008 9 (Suppl 1): 33.
Goodier M, Gregson J, Constantinou D, Steel A, Bower M,

Gazzard B & Gotch F
Lipopolysaccharide-induced activation of natural killer

cells from HIV-1 infected individuals
Lymph nodes involved by multicentric Castleman

disease among HIV-positive individuals are often
involved by Kaposi sarcoma
Strategies for Management of Antiretroviral Therapy

(SMART) Study Group, Emery S, Neuhaus JA, Phillips AN,
Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M,
Losso MH, Palfreeman A, Wood R.
Major clinical outcomes in antiretroviral therapy (ART)naive participants and in those not receiving ART at
baseline in the SMART study
J Infect Dis. 2008 Apr 15;197(8):1133-44
Pozniak A.
Management of HIV: still a long way to go

Br J Hosp Med (Lond). 2008 Mar;69(3):126
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus

E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M,
Montana JB, McHale M, Sullivan J, Ridgway C, Felstead
S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study
Teams.
Maraviroc for previously treated patients with R5 HIV-1

infection.
N Engl J Med. 2008 Oct 2;359(14):1429-41
FM Burns, A Johnson, J Nazroo, K Fenton; on behalf

of the SONHIA collaboration group (J. Ainsworth, J.
Anderson, R. Arthur M. Chikohora, A. Fakoya, I.Fakoya,
A. Hughes, E. Jungmann, S. Manney, L. Muromba, N.
Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K.
Sullivan.
Missed opportunities for earlier HIV diagnosis within
primary and secondary health care settings in the UK.
AIDS 2008; 22:115-22.
Molina J-M, Andrade-Villanueva J, Echevarria J,

Chetchotisakd P, Corral J, David N, Moyle G, Mancini M,
Percival L, Yang R, Thiry A, McGrath D, for the CASTLE Study
Team
Once-daily atazanavir/ritonavir versus twice-daily
lopinavir/ritonavir, each in combination with tenofovir
and emtricitabine, for management of antiretroviralnaive HIV-1-infected patients: 48 week efficacy and
safety results of the CASTLE study
The Lancet 2008: 372:646-55
Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J,

Schechter M.
Overcoming resistance to existing therapies in HIVinfected patients: the role of new antiretroviral
drugs
J Med Virol. 2008;80:565-76.
27
2008 continued
Coyne, KM, Cohen CE, Smith NA, Barton SE.
Patient-delivery partner medication
Int. J. STD & AIDS 2008;19:646
Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M,

Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin
C, Anderson J, Schwenk A, Leen C, Sabin CA; on behalf
of the UK Collaborative HIV Cohort (CHIC) Study Steering
Committee.
Patterns and predictors of the use of different
antiretroviral drug regimens at treatment initiation in
the UK.
HIV Med. 2008 Jan;9(1):47-56.
Dickinson L, Boffito M, Khoo SH, Schutz M, Aarons LJ,

Pozniak AL, Back DJ
Pharmacokinetic analysis to assess forgiveness of
boosted saquinavir regimens for missed or late
dosing.
J Antimicrob Chemother. 2008 Jul;62(1):161-7
Sousa M, Pozniak A, Boffito M.
Pharmacokinetics and pharmacodynamics of drug

interactions involving rifampicin, rifabutin and
antimalarial drugs.
J Antimicrob Chemother. 2008 Nov;62(5):872-8. Epub 2008

Aug 18
Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak
A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M.
Pharmacokinetics and safety of saquinavir/ritonavir and

omeprazole in HIV-infected subjects
Clin Pharmacol Ther. 2008 Jun;83(6):867-72.
Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak

A, Gazzard B, Moyle G
Pharmacokinetics of atazanavir/ritonavir once daily
and lopinavir/ritonavir twice and once daily over 72 h
following drug cessation.
Antivir Ther. 2008;13(7):901-7
Boffito M, Miralles D, Hill A.
Pharmacokinetics, efficacy, and safety of darunavir/

ritonavir 800/100 mg once-daily in treatment-naive and
experienced patients.
HIV Clin Trials. 2008 Nov-Dec;9(6):418-27.
V. Campbell, J. Krell, M. Stancliffe, M. Atkins, M. Habibi, M.

Nelson, B. Gazzard, M.Bower
Plasma HHV8 DNA viral load as a tumour marker for
multicentric Castlemans disease MCD
Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M,

Tsoukas C.
Potential for new antiretrovirals to address unmet needs

in the management of HIV-1 infection.
AIDS Patient Care STDS 2008;22:459-71
El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ,

Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD
Risk for opportunistic disease and death after

reinitiating continuous antiretroviral therapy in patients
with HIV previously receiving episodic therapy: a
randomized trial.
Ann Intern Med. 2008 Sep 2;149(5):289-99
Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG,

Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ,
Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE,
Choudhri S.
Safety, tolerability, pharmacokinetics, and efficacy of

an interleukin-2 agonist among HIV-infected patients
receiving highly active antiretroviral therapy.
J Interferon Cytokine Res. 2008 Feb;28(2):89-100
Underwood J, Scourfield A, Bell C, Harding V, Bower M &

Nelson M
Severe hepatotoxicity associated with darunavir
Byakika-Kibwika P, Lamorde M, Kalemeera F, DAvolio A,

Mauro S, Di Perri G, Ryan M, Mayanja-Kizza H, Khoo S, Back
D, Boffito M, Merry C.
Steady-state pharmacokinetic comparison of generic

and branded formulations of stavudine, lamivudine and
nevirapine in HIV-infected Ugandan adults.
J Antimicrob Chemother. 2008 Nov;62(5):1113-7.
Ftkenheuer G, Nelson M, Lazzarin A, Konourina I,

Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F,
Trottier B, Bellos N, Saag M, Cooper DA, Westby M,
Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead
S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2
Study Teams.
Subgroup analyses of maraviroc in previously treated
R5 HIV-1 infection.
N Engl J Med. 2008 Oct 2;359(14):1442-55
28
Ewings FM, Bhaskaran K, Nock, Porter K, D, McLean K,

Hawkins D, Fisher M, Fidler S, Gilson R, Brettle R, Johnson
M, Phillips A
Stebbing J, Ngan S, Ibrahim H, Charles P, Nelson M,

Kelleher P, Naresh KN, Bower M.
AIDS. 2008 Jan 2;22(1):89-95
Clin Exp Immunol. 2008, 154(3):399-405.
Survival following HIV infection of a cohort followed up

from seroconversion in the UK
The successful treatment of haemophagocytic syndrome

in patients with human immunodeficiency virusassociated multi-centric Castlemans disease
Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG,

Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.
V. Campbell, J. Krell, A. Scourfield, S. Mandalia, M. Nelson, T.

Powles, J.Stebbing, M. Bower
Switching from twice-daily abacavir and lamivudine

to the once-daily fixed-dose combination tablet of
abacavir and lamivudine improves patient adherence
and satisfaction with therapy.
HIV Med. 2008 Oct;9(8):667-72.
Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE
The use of antidepressants and risk of cancer in

individuals infected with the human immunodeficiency
virus
Cohen CE, Coyne KM, Mandalia S, Waters AM, Sullivan AK
The face of HIV and AIDS: can we erase the stigma?
Time to use text reminders in genitourinary medicine

clinics
Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B,

Moyle G.
Lagos D, Vart RJ, Gratrix F, Westrop SJ, Emuss V, Wong PP,

Robey R, Imami N, Bower M, Gotch F, Boshoff C
AIDS Care. 2008 Apr; 20 (4) 485-7
The impact of HIV tropism on decreases in CD4 cell

count, clinical progression, and subsequent response to
a first antiretroviral therapy regimen.
Clin Infect Dis. 2008;46:1617-23
J.Krell, A. Bazeos, V. Campbell, V. Harding, T. Powles, J.

Stebbing, S. Mandalia, M. Bower.
The incidence of HIV-associated multicentric Castlemans

disease
Waters L, Nelson M, Mandalia S, Bower M, Powles T,

Gazzard B, Stebbing J.
The risks and incidence of K65R and L74V mutations

and subsequent virologic responses
Clin Infect Dis. 2008 Jan 1;46(1):96-100
Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG.

The role of transbronchial fine needle aspiration in an
integrated care pathway for the assessment of patients
with suspected lung cancer
J Thorac Oncol. 2006; 1(4):324-7.
Turner C, Cohen CE, Sabin C, Tosswill J, Best J, Taylor G, de

Ruiter A, Barlow D, Smith NA.
The Seroepidemiology of HTLV-1 amongst
genitourinary attendees in South East London.
Journal of Clinical Virology. 2008 Oct;43(2):253-4. Epub

2008 Aug 8
Int J STD AIDS 2008 Jan; 19 (1): 12-3.
Toll-like receptor 4 mediates innate immunity to Kaposi

sarcoma herpesvirus
Cell Host Microbe. 2008 Nov 13;4(5):470-83
Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V,

Higgins N, Grundy A, Moyle GJ
Treatment of Altered Body Composition in HIVAssociated Lipodystrophy: Comparison of

Rosiglitazone, Pravastatin, and Recombinant Human
Growth Hormone
HIV Clin Trials 2008;9(4):253267
Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels

M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J,
Williams I, Gazzard B.
Treatment outcome and cost-effectiveness of different
highly active antiretroviral therapy regimens in the UK
(1996-2002).
Int J STD AIDS. 2008 May;19(5):297-304.
United Kingdom Collaborative HIV Cohort Study, Lee KJ,

Dunn D, Porter K, Bansi RG, Hill T, Phillips AN, Sabin CA,
Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B,
Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C.
Treatment switches after viral rebound in HIV-infected

adults starting antiretroviral therapy: multicentre cohort
study.
AIDS. 2008 Oct 1;22(15):1943-50.
Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard

B, Stebbing J
Triple-class antiretroviral agent resistance in a large
cohort: prevalence and clinical outcomes.
Arch Intern Med. 2008, ;168(17):1926-7.
29
2008 continued
Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B,
Bower M
Use of antidepressants and risk of cancer in individuals

infected with HIV
J Clin Oncol. 2008 May 10;26(14):2305-10
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S,

Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART
Study Group.
Viral resuppression and detection of drug resistance

following interruption of a suppressive non-nucleoside
reverse transcriptase inhibitor-based regimen
AIDS. 2008 Nov 12;22(17):2279-89.
Ancock B, Bower M, Gazzard BG, Nelson M
Vitamin D deficiency in the in-patients HIV population:

cause or effect?
1):P116 (10November2008)
Bhattacharya R, Barton SE, Catalan J
When good news is bad news: psychological impact of

false positive diagnosis of HIV
AIDS Care. 2008 May; 20(5): 560-4
30

SSAT Research Publications 2008 - 2014

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

SSAT Research Publications 2008 - 2014

Uploaded by

Copyright:

Available Formats

St Stephens AIDS Trust

Clinical Research Publications 2008 2014

ST STEPHENS AIDS TRUST CLINICAL RESEARCH PUBLICATIONS 2008 - 2014

St Stephens Centre, 369 Fulham Road, London SW10 9NH

ST STEPHENS AIDS TRUST CLINICAL RESEARCH PUBLICATIONS 2008 - 2014

St Stephens AIDS Trust

promote clinical research into the treatment of HIV and

Charity has developed a strong track record in clinical

ST STEPHENS AIDS TRUST CLINICAL RESEARCH PUBLICATIONS 2008 - 2014

CLINICAL RESEARCH PUBLICATIONS 2008-2014

Parikh ND, Martel-Laferriere V, Kushner T, Childs K, Vachon

Chacko L, Chamberlain F, Mandalia S, Nelson M

Do resistance patterns vary between different FTC

McFaul K, Liptrott N, Cox A, Martin P, Egan D, Owen A, Kelly

Evolution of cellular and viral resistance in HIV patients

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S,

Longley J, Redlin S, Balachandran K, Holmes P, Nelson M &

Tull T, Papineni P, Cook C, Mee J, Bower M, Morar N,

Paraneoplastic pemphigus in patient infected with HIV

Prospective stage stratified approach to AIDS related

Smith M, Pealing J, McCann S, Balachandran K, Nelson M &

Keay R, Singh G, Abdul-Latif M, Rayment M, Nelson M

Shigella flexneri enteritis in risk- taking HIV infected

Chacko L, Chamberlain F, Mandalia S, Nelson M

J Infect 2014 Jan; 68 (1); 103-4

J Acqui Immune Defic Syndr 2014 Jan 1; 65 (1): 78-81

Ferras Alwan, Annie He, Silvia Montoto, Shireen Kassam,

Five-year safety evaluation of Maraviroc in HIV 1

Nightingale A, Ratcliffe D, Leonidou L, Margetts A, Asboe D,

Dhoot S, Balachandran K, Tittle V, Bunker C, Nelson M,

Immunological function in HIV-seronegative men

The addition of Rituximab to CODOX-M/IVAC

Bulteel N, Banso-Matharu L, Churchill D, Dunn D, Bibby D,

ST STEPHENS AIDS TRUST CLINICAL RESEARCH PUBLICATIONS 2008 - 2014

CLINICAL RESEARCH PUBLICATIONS 2008-2014

Rayment M, Doku E, Thornton A, Pearn M, Sudhanva M,

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR,

96-Week results of abacavir/lamivudine versus

A benchmark for management of drug resistant HIV.

Martin TC, Martin NK, Naresh KN, Nelson M

A traumatic splenic rupture secondary to chronic HIV

Revell AD, Wang D, Wood R, Morrow C, Templeman H,

Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D,

Automatic Oral Fluid-Based HIV Testing in HIV Screening

Abdel Malek R, Cox S, Bower M, Farag D & Alsirafy S.

Availability of informal caregivers for palliative care

Mehta P, Nelson M, Brand A, Boag F

Hematol Int. 2013 Jan; 33 (1): 235-8

Can we stop CD4+ testing in patients with HIV 1 RNA

Jagit Singh GK, Ijaz S, Rockwood N, Farnworth SP, Devitt

Chronic Hepatitis E as a cause for cryptogenic cirrhosis

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N,

Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd

Bower M, Della Pria A, Flook M, Hayward K, Januszewski A,

ST STEPHENS AIDS TRUST CLINICAL RESEARCH PUBLICATIONS 2008 - 2014

CLINICAL RESEARCH PUBLICATIONS 2008-2014

Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA,

Efficacy and safety of lersivirine (UK-453,061) versus

Nithianathan V, Singh GKJ, Bower M & Nelson M

Raben D, Delpech V, de Wit J, Sullivan A, Lazarus J, Dedes

Emerging patterns of integrase inhibitor

HIV Med 2013; 14 Suppl 3:1-5

OConnor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay

Conclusions from the HIV in Europe Copenhagen 2012